The U.S. Congress is advancing three legislative and regulatory measures to scrutinize and potentially restrict partnerships between American biopharma companies and Chinese biotech firms, citing national security concerns. These actions target the flow of U.S. capital and technology to China amid a surge in deals, with innovative drug out-licensing transactions exceeding $60 billion in the first quarter of 2026 alone.
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
Big drug companies said Trump administration pricing deals had little to no noticeable impact on earnings, though details remain confidential. Novo Nordisk and Eli Lilly described bigger effects tied to lower GLP-1 cash-pay prices and expanded Medicare coverage.
Microdosing GLP-1 medications like Ozempic and Wegovy has emerged as a weight-loss trend, but health experts warn there is no scientific data supporting the practice and caution about potential safety risks.
Novo Nordisk's experimental weight loss drug CagriSema achieved 23% weight loss after 84 weeks compared to 25.5% with Eli Lilly's tirzepatide in a head-to-head Phase 3 trial, sending Novo shares down 15% in Copenhagen.
GLP-1 weight loss drugs show increasing efficacy but raise concerns about excessive weight loss, side effects, and the rise of unregulated compounded versions sold online.
Weight-loss drugs like Ozempic and Wegovy are creating visible facial changes in celebrities while scams targeting consumers surge nationwide. Multiple public figures have disclosed using GLP-1 medications, with some experiencing significant side effects.
